David Scott.

David Scott , Varian UK & Ireland Sales Manager, added: This is a wonderful new resource for cancer patients in southeast Ireland and Varian is pleased to have been selected to equip the center with advanced cancer therapy machines and software the tumor and the Irish population has private health insurance and as a leader for Irish private health centers and PPP projects in Ireland and the United Kingdom is Varian proud to be a part this project. .

Notwithstanding all notwithstanding all events in this press release, the company described quarterly and annual financial results submitted under these risks and uncertainties in the Company’s Annual Report on Form 10 – K and other reports filed from time to time by the Company with the U.S. Securities and Exchange Commission and the actual results may differ. From the results currently expected.. Forward-Looking Statementsthe statements in this news release regarding future business, events, expectations, estimates, and other similar matters, including, but not limited to, statements about the conditions and may , expect , are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.As a result, Dynal to for long-term IVD assay development, by the earliest phases, meets all present and future manufacture and regulatory requirements. Has to offer now be be expected as part of a Invitrogen, still the quality of the markets we. Day Dynabead product range most cell separation for basic research and clinical research, that is, theyranscriptomics, proteomics, diagnostics and more. Dynal offers customized products on OEM basis for major volumes users.. Dynabead be voted magnetic separation tool by are the world’s best by superparamagnetic magnetic beads to both research and diagnostic applications. As a result, the leading IVD enterprises Dynabead for over 15 years for over 15 years.